- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/16 - Anti-Parkinson drugs
Patent holdings for IPC class A61P 25/16
Total number of patents in this class: 5364
10-year publication summary
|
173
|
223
|
370
|
458
|
391
|
455
|
466
|
460
|
387
|
227
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7921 |
70 |
| Takeda Pharmaceutical Company Limited | 2709 |
59 |
| H. Lundbeck A/S | 1246 |
47 |
| Hoffmann-La Roche Inc. | 3422 |
46 |
| Janssen Pharmaceutica N.V. | 3383 |
36 |
| Sumitomo Pharma Co., Ltd. | 585 |
36 |
| The Regents of the University of California | 19929 |
33 |
| Taisho Pharmaceutical Co., Ltd. | 870 |
29 |
| Genentech, Inc. | 3980 |
28 |
| Sumitomo Dainippon Pharma Co., Ltd. | 216 |
27 |
| Bristol-myers Squibb Company | 4893 |
26 |
| Merck Sharp & Dohme LLC | 3741 |
25 |
| Novartis AG | 10850 |
24 |
| Pfizer Inc. | 3381 |
24 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 827 |
24 |
| Eisai R&D Management Co., Ltd. | 1231 |
24 |
| AstraZeneca AB | 2908 |
23 |
| BIAL - Portela & CA, S.A. | 220 |
23 |
| The Johns Hopkins University | 5669 |
22 |
| Osaka University | 3374 |
22 |
| Other owners | 4716 |